Assessment or central dopaminergic function using plasma-free homovanillic acid after debrisoquin administration

M. A. Riddle, J. F. Leckman, D. J. Cohen, M. Anderson, S. I. Ort, K. A. Caruso, B. A. Shaywitz

Research output: Contribution to journalArticlepeer-review

Abstract

Central dopaminergic (DA) function in children and adults was assessed by monitoring plasma-free levels of the dopamine metabolite homovanillic acid (pHVA) before and after a single oral dose and chronic oral administration of debrisoquin. Debrisoquin inhibits peripheral metabolism of dopamine to HVA and does not cross the blood-brain barrier. By reducing peripheral formation of HVA through the use of debrisoquin, the remaining HVA in plasma more accurately reflects central DA activity. Debrisoquin administration resulted in marked reductions of pHVA in each of 12 patients studied. Eleven of the 12 subjects tolerated debrisoquin without physical or behavioral side effects. The debrisoquin administration method appears to be a safe and potentially valid technique for evaluating aspects of central dopaminergic function in children and adults.

Original languageEnglish (US)
Pages (from-to)31-43
Number of pages13
JournalJournal of Neural Transmission
Volume67
Issue number1-2
DOIs
StatePublished - Mar 1986
Externally publishedYes

Keywords

  • Debrisoquin
  • Tourette's syndrome
  • homovanillic acid

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint

Dive into the research topics of 'Assessment or central dopaminergic function using plasma-free homovanillic acid after debrisoquin administration'. Together they form a unique fingerprint.

Cite this